Clinical Trial

ENCOrafenib With Binimetinib in bRAF NSCLC

Name: ENCOrafenib With Binimetinib in bRAF NSCLC — clinical trial record (NCT04526782)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ENCO-BRAF

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

Protocol Amendment History 1 change

minor Completion pushed: 2026-03 -> 2027-03 2026-08-12

Trial Details

NCT Number	NCT04526782
Lead Sponsor	Intergroupe Francophone de Cancerologie Thoracique
Conditions	Non Small Cell Lung Cancer, BRAF V600E
Enrollment	119 participants
Start Date	2021-01-19
Primary Completion	2025-07-16 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-11